These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20486173)

  • 1. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
    Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY
    Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J; Wraight CJ; Freier SM; Peralta E; Atley LM; Monia BP; Gleave ME; Cox ME
    Prostate; 2010 Feb; 70(2):206-18. PubMed ID: 19790231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.